SOURCE: Paragon Financial Limited

Paragon Financial Limited

September 28, 2011 08:16 ET

Momenta Pharmaceuticals and Gilead Sciences Brace for More Competition

The Paragon Report Provides Equity Research on Momenta Pharmaceuticals and Gilead Sciences

NEW YORK, NY--(Marketwire - Sep 28, 2011) - The Paragon Report examines investing opportunities in the Biotechnology and Drugs industry and provides equity research on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) and Gilead Sciences, Inc. (NASDAQ: GILD). Access to the full company reports can be found at:

With several patent cliffs looming, companies in the Biotechnology and Drugs sector are adopting different strategies to ensure their own health once several drugs open up to generic copies. One major trend has been to focus on emerging healthcare markets where growth is strong in order to help offset upcoming domestic uncertainty. Future growth of the pharmaceutical industry is expected to take place in emerging markets including India, China, Brazil, South Africa and others. This is because the economies of these countries are booming and the middle class in these nations continues to rapidly grow. "Emerging market activity will be a source of out-performance for pharma stocks," thinks Dr. Gbola Amusa, Managing Director, Global Pharmaceuticals Sector Co-ordinator and Head of European Pharmaceuticals Research at UBS. "Emerging markets for pharma are now just big enough to matter," said Dr. Amusa. "They are up from 5% of [Big Pharma's] business five years ago to 20-30 percent."

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Biotechnology and Drugs industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Momenta Pharmaceuticals is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides such as heparan-sulfate proteoglycans (HSPGs). A week ago the company said it is suing three generic drugmakers for allegedly infringing patents used to produce its generic version of Lovenox, a popular blood thinning drug.

Gilead Sciences focuses on the development and commercialization of human therapeutics for life threatening diseases. The Company has operations in North America, Europe and Asia Pacific.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at